Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for ordinary fully paid shares. The update, dated 4 March 2026, reports that a total of 3,913,667 shares had been repurchased prior to the previous trading day, with an additional 57,410 shares bought back on the previous day.
The buy-back, initially notified in August 2025 and updated daily, signals ongoing capital management by CSL that can support earnings per share by reducing the share count. Regular disclosure of the repurchase volumes provides transparency for investors tracking the pace of the program and its potential implications for shareholder returns and market liquidity.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$163.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a publicly listed company on the ASX, trading under the code CSL and issuing ordinary fully paid shares. The company operates in the broader healthcare and biotechnology investment universe, attracting institutional and retail shareholders who closely monitor its capital management and buy-back activities.
Average Trading Volume: 1,132,511
Technical Sentiment Signal: Sell
Current Market Cap: A$71.46B
Learn more about CSL stock on TipRanks’ Stock Analysis page.